arma Partnerships conference scheduled to be held in San Francisco on December 13.
Windhover's Bio/Pharma Partnerships is an exclusive partnering conference that links global biotechnology and pharmaceutical companies to explore potential collaborations, mergers and acquisitions, alliances and financing activities.
Suven has been working on innovative technology platforms, particularly in the class of selective 5-HT compounds for development as therapeutic agents in the treatment of neuro-degenerative disorders like Alzheimer's alltention deficient hyperactivity, Hyntington's, Parkinson and
schizophrenia and obesity, according to a press release issued today.
Suven Life has filled 26 products patents under the Patent Cooperation Treaty (PCT) of which 10 entered the national phase. Suven has already filed its first investigational new drug (IND) application with the Drugs Controller General of India (DCGI) to conduct the clinical phase-I study on their developmental candidate SUVN-502.
Suven, since September 2006, is also working as a collaborative research partner (CRP) with Elli Lilly to discover and develop new chemical entities (NCEs) for an unmet medical need in central nervous system (CNS) therapeutic area.
